These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20362429)

  • 1. Translational research on u-PAR.
    Allgayer H
    Eur J Cancer; 2010 May; 46(7):1241-51. PubMed ID: 20362429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors.
    Leupold JH; Yang HS; Colburn NH; Asangani I; Post S; Allgayer H
    Oncogene; 2007 Jul; 26(31):4550-62. PubMed ID: 17297470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation and clinical significance of urokinase-receptor (u-PAR), an invasion-related molecule.
    Allgayer H
    Z Gastroenterol; 2006 Jun; 44(6):503-11. PubMed ID: 16773517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
    Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
    Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular regulation of an invasion-related molecule--options for tumour staging and clinical strategies.
    Allgayer H
    Eur J Cancer; 2006 May; 42(7):811-9. PubMed ID: 16617013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis.
    Fuchs T; Allgayer H
    Biol Chem; 2003 May; 384(5):755-61. PubMed ID: 12817472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
    Allgayer H; Aguirre-Ghiso JA
    APMIS; 2008; 116(7-8):602-14. PubMed ID: 18834405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
    Zhao W; Wang X; Qu B; Huang X; Wang H
    Chin Med J (Engl); 2002 May; 115(5):702-4. PubMed ID: 12133538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
    Paciucci R; Torà M; Díaz VM; Real FX
    Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
    Durand MK; Bødker JS; Christensen A; Dupont DM; Hansen M; Jensen JK; Kjelgaard S; Mathiasen L; Pedersen KE; Skeldal S; Wind T; Andreasen PA
    Thromb Haemost; 2004 Mar; 91(3):438-49. PubMed ID: 14983218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Problems of tumor progression: doubts or hopes at the turn of the Millennium?].
    Tímár J
    Orv Hetil; 2000 Apr; 141(17):891-9. PubMed ID: 10827469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.
    Kim SJ; Shiba E; Taguchi T; Watanabe T; Tanji Y; Kimoto Y; Izukura M; Takai SI
    Anticancer Res; 1997; 17(2B):1373-8. PubMed ID: 9137501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
    Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and function of the urokinase receptor.
    Møller LB
    Blood Coagul Fibrinolysis; 1993 Apr; 4(2):293-303. PubMed ID: 8388742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.
    Schewe DM; Biller T; Maurer G; Asangani IA; Leupold JH; Lengyel ER; Post S; Allgayer H
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8538-48. PubMed ID: 16361535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
    Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Hashiba Y; Kawashiri S; Tanaka A; Nakagawa K; Matsuoka Y; Kogo M; Yamamoto E
    Oral Oncol; 2005 Nov; 41(10):971-7. PubMed ID: 16129656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
    Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
    Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.